Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter December 4, 2012

Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling

  • Bryan T. Richardson , Christopher F. Dibble , Asya L. Borikova and Gary L. Johnson EMAIL logo
From the journal Biological Chemistry

Abstract

Cerebral cavernous malformation (CCM) involves the homozygous inactivating mutations of one of three genes, ccm1, -2, or -3 resulting in hyperpermeable blood vessels in the brain. The CCM1, -2, and -3 proteins form a complex to organize the signaling networks controlling endothelial cell physiology including actin dynamics, tube formation, and adherens junctions. The common biochemical defect with the loss of CCM1, -2, or -3 is increased RhoA activity leading to the activation of Rho-associated coiled coil-forming kinase (ROCK). Inhibition of the ROCK rescues CCM endothelial cell dysfunction, suggesting that the inhibition of RhoA-ROCK signaling may be a therapeutic strategy to prevent or arrest the progression of the CCM lesions.


Corresponding author: Gary L. Johnson, Department of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA

Received: 2012-6-28
Accepted: 2012-8-13
Published Online: 2012-12-04
Published in Print: 2013-01-01

©2012 by Walter de Gruyter Berlin Boston

Downloaded on 26.4.2024 from https://www.degruyter.com/document/doi/10.1515/hsz-2012-0243/html
Scroll to top button